Patent details

LUC50006 Product Name: Belzutifan, ou l'un de ses sels pharmaceutiquement acceptables, en particulier le belzutifan

Basic Information

Publication number:
LUC50006
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP181855578
Legal Status:
Pending & Published
Application number:
LUC50006
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/24/1893
Marketing Authorization Type:
Marketing Authorization Date:
14/02/2025
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
07/05/2025
First Marketing Authorization date:
14/02/2025
Grant date:
Activation date:
Publication date:
08/05/2025
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
05/09/2039
SPC Extension Expiration:
05/09/2039
Rejection date:
Withdrawal date:

Owner

From:
07/05/2025
 
 

Name:
Peloton Therapeutics, Inc.
Address:
2330 Inwood Road Suite 226, Dallas, TX 75235-7323, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
07/05/2025
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

Bulletin Heading:
SPC1
Bulletin edition number:
2025/07
Publication date:
04/06/2025
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

Annual Fees

Annual Fee Due Date:
02/10/2034
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
08/05/2025 Publication 1
07/05/2025 Application Form 5
07/05/2025 General Document 43
07/05/2025 Outgoing Correspondence 2
07/05/2025 General Document 1
07/05/2025 General Document 13
07/05/2025 General Document 3
08/05/2025 Outgoing Correspondence 1